Q2 Earnings Estimate for VIR Issued By Leerink Partnrs

Vir Biotechnology, Inc. (NASDAQ:VIR) – Leerink Partnrs issued their Q2 2025 earnings estimates for Vir Biotechnology in a report issued on Sunday, January 12th. Leerink Partnrs analyst R. Ruiz forecasts that the company will earn ($0.95) per share for the quarter. The consensus estimate for Vir Biotechnology’s current full-year earnings is ($3.36) per share. Leerink Partnrs also issued estimates for Vir Biotechnology’s Q3 2025 earnings at ($0.88) EPS and Q4 2025 earnings at ($0.87) EPS.

Vir Biotechnology (NASDAQ:VIR) last announced its earnings results on Thursday, October 31st. The company reported ($1.56) earnings per share for the quarter, missing the consensus estimate of ($1.05) by ($0.51). Vir Biotechnology had a negative return on equity of 36.71% and a negative net margin of 678.40%. The business had revenue of $2.38 million for the quarter, compared to analysts’ expectations of $5.54 million. During the same period in the previous year, the company earned ($1.22) earnings per share. Vir Biotechnology’s quarterly revenue was down 9.8% on a year-over-year basis.

Several other research analysts have also recently commented on VIR. JPMorgan Chase & Co. boosted their target price on Vir Biotechnology from $10.00 to $14.00 and gave the stock a “neutral” rating in a research note on Thursday, January 9th. Morgan Stanley raised Vir Biotechnology from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $10.00 to $20.00 in a research report on Thursday, January 9th. HC Wainwright restated a “buy” rating and set a $110.00 target price on shares of Vir Biotechnology in a research note on Friday. Needham & Company LLC reiterated a “buy” rating and issued a $19.00 price target on shares of Vir Biotechnology in a research note on Wednesday, November 20th. Finally, Leerink Partners boosted their price target on shares of Vir Biotechnology from $18.00 to $20.00 and gave the stock an “outperform” rating in a report on Monday. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $34.83.

Vir Biotechnology Trading Down 13.1 %

Vir Biotechnology stock opened at $10.52 on Tuesday. The firm has a market capitalization of $1.45 billion, a P/E ratio of -2.68 and a beta of 0.51. Vir Biotechnology has a twelve month low of $6.56 and a twelve month high of $14.45. The stock’s fifty day simple moving average is $8.26 and its 200-day simple moving average is $8.36.

Hedge Funds Weigh In On Vir Biotechnology

Several hedge funds have recently made changes to their positions in VIR. Rhumbline Advisers increased its holdings in shares of Vir Biotechnology by 4.3% in the 2nd quarter. Rhumbline Advisers now owns 238,504 shares of the company’s stock valued at $2,123,000 after acquiring an additional 9,817 shares during the period. Victory Capital Management Inc. grew its position in Vir Biotechnology by 41.5% during the 2nd quarter. Victory Capital Management Inc. now owns 65,573 shares of the company’s stock worth $584,000 after purchasing an additional 19,216 shares during the last quarter. Los Angeles Capital Management LLC acquired a new position in Vir Biotechnology in the second quarter valued at $119,000. Quest Partners LLC raised its holdings in shares of Vir Biotechnology by 142.1% in the second quarter. Quest Partners LLC now owns 12,695 shares of the company’s stock valued at $113,000 after buying an additional 7,452 shares during the last quarter. Finally, American Century Companies Inc. boosted its stake in shares of Vir Biotechnology by 12.7% during the second quarter. American Century Companies Inc. now owns 168,235 shares of the company’s stock worth $1,497,000 after buying an additional 18,967 shares during the period. Hedge funds and other institutional investors own 65.32% of the company’s stock.

Insider Transactions at Vir Biotechnology

In related news, Director Vicki L. Sato sold 10,960 shares of Vir Biotechnology stock in a transaction on Wednesday, January 8th. The shares were sold at an average price of $12.52, for a total transaction of $137,219.20. Following the sale, the director now directly owns 1,312,391 shares in the company, valued at $16,431,135.32. This trade represents a 0.83 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In the last 90 days, insiders have sold 14,786 shares of company stock valued at $170,172. Corporate insiders own 15.60% of the company’s stock.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).